SHANGHAI, Sept. 5, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, and Pakistan’s The Searle Company Limited (PSX: SEARL, hereinafter “Searle”) jointly announced that two denosumab products, 9MW0311 and 9MW0321, have received marketing authorization from Drug Regulatory Authority of Pakistan (DRAP). This marks both Pakistan’s first regulatory approval for a denosumab biosimilar and Mabwell’s first overseas marketing authorization for its products.
As a key Belt and Road Initiative partner with a population of 240 million, Pakistan presents substantial pharmaceutical market potential, aligning with Mabwell’s strategic expansion into high-growth emerging markets. Earlier, Mabwell entered into a licensing agreement with Searle to facilitate local fill-finish and commercialization of Denosumab in Pakistan.
Mr. Hu Huiguo, Board Member, Senior Vice President and Board Secretary of Mabwell, said, “The successful approval of denosumab in Pakistan provides local patients with enhanced treatment options and high-quality biologics, marking another milestone in Mabwell’s global commercialization strategy. Moving forward, we remain committed to expanding the product’s commercialization to additional countries, thereby improving global accessibility to denosumab injections and meeting the therapeutic needs of more patients worldwide.”
“With the launch of denosumab, we improve the accessibility of this product, and reaffirm our position as a pioneer in biosimilars in Pakistan,” said Tahir Ahmed, CEO of Searle, “This approval is a testament to our continued dedication to bringing high-quality, life-saving therapeutics to the region. We remain focused on improving patient outcomes through continued scientific excellence and strategic collaboration.”
About 9MW0311
9MW0311 is a recombinant fully humanized anti-RANKL monoclonal antibody injection (60mg), developed as a Prolia® biosimilar. On March 28, 2023, the marketing application for 9MW0311 was approved by the National Medical Products Administration (NMPA) for the treatment of postmenopausal women with osteoporosis at high risk of fracture in China. Additional supplemental applications are planned to expand indications, including: osteoporosis in men at high risk of fracture, and glucocorticoid-induced osteoporosis in patients at high fracture risk. According to Frost & Sullivan data, the global market size for RANKL monoclonal antibody therapies in osteoporosis treatment has reached $1.317 billion in 2024.
About 9MW0321
9MW0321 is a recombinant fully humanized anti-RANKL monoclonal antibody injection (120mg) developed as a XGEVA® biosimilar. The NMPA of China granted marketing approval for 9MW0321 on March 29, 2024, establishing it as China’s first approved XGEVA® biosimilar. It is indicated for the treatment of adults and skeletally mature adolescents (defined as at least 1 mature long bone and weighing ≥ 45 kg) with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Mabwell is currently advancing supplementary applications to extend 9MW0321’s indications to include malignancies associated with bone metastasis. BeOne Medicines and Amgen reported commercial performance data showing XGEVA® achieved annual sales of RMB 1.598 billion in China and USD 2.225 billion globally during 2024, with first half 2025 sales reaching RMB 1.090 billion in China and USD 1.098 billion worldwide. Future growth is anticipated to be predominantly driven by expansion in China and emerging markets.
About Searle
Established in 1965, The Searle Company Limited is among Pakistan’s leading pharmaceutical companies, with eight state-of-the-art manufacturing facilities, including a dedicated biotechnology plant. With operations in over 20 countries and rapid expansion across multiple global regions, Searle is committed to delivering innovative treatments for life-threatening conditions. The company’s biosimilar portfolio is among the most comprehensive in the region.
About Mabwell
Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. The company provides more effective and accessible therapy and innovative medicines to fulfill global medical needs, focusing on oncology and aging-related disease indications. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from ideas to reality”. For more information, please visit www.mabwell.com/en.
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.
View original content:https://www.prnewswire.com/news-releases/mabwell-secures-pakistans-first-denosumab-injection-approval-302547752.html
SOURCE Mabwell
